RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Kidney Failure

In brief

An unmet medical need exists for therapeutic regimens in transplantation that allow immediate postoperative graft function, thereby improving graft survival. Delayed graft function (DGF) after transplantation is the most common complication affecting kidney allographs in the immediate transplant period. The specific aim of this study is to evaluate the effect of recombinant human C1-inhibitor (rhC1INH), as a kidney recipient intra- and post operative treatment strategy to decrease systemic inflammation and decrease the incidence of DGF from donation after cardiac death donors (DCD).

Key facts

Study ID
NCT03791476
Run by
University of Wisconsin, Madison
People needed
20
Starts
2019-06-21
Expected to finish
2022-01-01
Last updated by the study team
2020-12-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.